Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBIT (2019 - 2025)

Harmony Biosciences Holdings' EBIT history spans 7 years, with the latest figure at $38.6 million for Q4 2025.

  • For Q4 2025, EBIT fell 30.81% year-over-year to $38.6 million; the TTM value through Dec 2025 reached $208.5 million, up 9.25%, while the annual FY2025 figure was $208.5 million, 9.25% up from the prior year.
  • EBIT for Q4 2025 was $38.6 million at Harmony Biosciences Holdings, down from $65.5 million in the prior quarter.
  • Across five years, EBIT topped out at $65.5 million in Q3 2025 and bottomed at $11.9 million in Q3 2022.
  • The 5-year median for EBIT is $40.3 million (2023), against an average of $40.0 million.
  • The largest annual shift saw EBIT surged 442.05% in 2023 before it tumbled 54.47% in 2024.
  • A 5-year view of EBIT shows it stood at $28.6 million in 2021, then soared by 66.3% to $47.6 million in 2022, then dropped by 15.58% to $40.2 million in 2023, then skyrocketed by 38.64% to $55.7 million in 2024, then tumbled by 30.81% to $38.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EBIT are $38.6 million (Q4 2025), $65.5 million (Q3 2025), and $48.2 million (Q2 2025).